# A191 THE NEURAL SIGNAL, CALCITONIN GENE-RELATED PEPTIDE (CGRG) ENHANCES A REGULATORY PHENOTYPE IN THE HUMAN IL-4-TREATED MACROPHAGE

**Authors:** B E Callejas Pina, J A Sousa, K Flannigan, A Wang, S Li, S Rajeev, R Panaccione, D McKay

PMC · DOI: 10.1093/jcag/gwad061.191 · Journal of the Canadian Association of Gastroenterology · 2024-02-14

## TL;DR

This study shows that calcitonin gene-related peptide enhances the anti-inflammatory and wound-healing abilities of IL-4-treated macrophages in a mouse model of colitis.

## Contribution

The novel finding is that CGRP signaling boosts the reparative and anti-colitic functions of IL-4-treated macrophages.

## Key findings

- CGRP-treated IL-4 macrophages showed increased anti-colitic effects in mice compared to untreated macrophages.
- Conditioned medium from CGRP-treated macrophages improved epithelial wound healing in vitro.
- COX-1 and PGD2 are involved in the enhanced repair function of CGRP-treated macrophages.

## Abstract

Interlukin-4 activated human macrophages (M(IL4) promote epithelial wound healing and exert an anti-colitic effect in a murine model. Blood monocyte-derived M(IL4)s from healthy donors and individuals with Crohn’s disease had increased mRNA expression of the calcitonin gene-related peptide (CGRP) receptor chain, RAMP1, raising the issue of neural modulation of the M(IL4)s reparative function.

To determine if CGRP-RAMP1 signalling in human IL-4 treated macrophages enhances the anti-colitic phenotype.

Peripheral blood mononuclear cells from healthy volunteers (HD) and individuals with Crohn’s disease were cultured on plastic (2h, 37°C) and non-adherent cells removed. The adherent cells were cultured with recombinant hM-CSF (10 ng/ml) for 7 days. The resultant macrophages (2.5×105) were differentiated with IL-4 (48h 10 ng/mL). In other cells, CGRP (10 nM) was added 24h after IL-4 and phenotype assessed by qPCR. Rag1-/- mice were treated with M(IL4)±CGRP (1x106 i.p.): 48h later, colitis was induced by oxazolone. FITC dextran was used to evaluate epithelial barrier integrity. A wound healing assay was conducted using CaCo2 epithelial cells and conditioned medium (CM,1:2 dilution) from the different treatments. Prostaglandin D2 production was evaluated by ELISA and cyclooxygenase (COX)-1 and -2 activity inhibited using SC560 and indomethacin.

Compared to non-treated macrophages (M(0)), M(IL4)s from HD had increased RAMP1 and CLR mRNA. M(IL4)s treated with CGRP showed enhanced expression of CD206, CCL26, RAMP1 and CCL18. When delivered systemically to oxazolone-treated rag1-/- mice, M(IL4,CGRP) had an anti-colitic effect superior to M(IL4)s from the same healthy blood donor. Use of the the human colon CaCo2 cell in vitro wounding model revealed that CM from M(IL4,CGRP) had increased amounts of TGFb and increased wound-healing capacity compared to matched M(IL4)-CM. Moreover, M(IL4,CGRP)s displayed increased COX-1 and PGD2. CM from M(IL4,CGRP)s treated with indomethacin or SC-560 to inhibit COX1 activity failed to promote repair of wounded CaCo2 cell monolayers.

Neuronal input is revealed as an important local modifier capable of boosting the anti-colitic effect of autologous M(IL4) transfer to treat enteric inflammation.

CCCHelmsley Charity

## Linked entities

- **Genes:** RAMP1 (receptor activity modifying protein 1) [NCBI Gene 10267], DCLK3 (doublecortin like kinase 3) [NCBI Gene 85443], CCL26 (C-C motif chemokine ligand 26) [NCBI Gene 10344], CCL18 (C-C motif chemokine ligand 18) [NCBI Gene 6362], COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513]
- **Proteins:** CALCA (calcitonin related polypeptide alpha), TGFB1 (transforming growth factor beta 1)
- **Chemicals:** IL-4 (PubChem CID 171905173), CGRP (PubChem CID 168324612), SC560 (PubChem CID 4306515), indomethacin (PubChem CID 3715), oxazolone (PubChem CID 1712094)
- **Diseases:** Crohn’s disease (MONDO:0005011), colitis (MONDO:0005292)
- **Species:** Mus musculus (taxon 10090), Homo sapiens (taxon 9606)

---
Source: https://tomesphere.com/paper/PMC10872096